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The New Leaf Opportunities campaign 
has highlighted the economic 
benefits, innovations and investment 
opportunities that medical cannabis 
and CBD can bring to the UK. It has also 
focused on how celebrating this will 
lead to a more vibrant cannabis sector.
This report has honed in on the 
opportunities that medical cannabis 
and CBD bring through an economic, 
innovation and regulatory lens. 
Chapter one focuses on the economic 
opportunity, using existing evidence to 
paint a clear picture as to why the UK is 
an attractive jurisdiction for business. 
An analysis of the major cannabis 
companies was performed to showcase 
the global opportunity for medical 
cannabis. Using a number of countries 
and US states, a market estimate was 
calculated for the UK, which stands at 
£1.2 billion. Using job statistics from 
US states with only a medical cannabis 
industry (i.e. no adult-use market), an 
estimate for the UK was formed; over 
41,000 jobs could be created in the 
UK medical cannabis sector with 
an additional approximate 17,000 
ancillary jobs.
Chapter two examines the 
opportunities for innovation through 
a case study analysis of two cannabis 
companies: Kanabo and CiiTECH.  
As the barriers to prohibition break 
down, the industry requires evidence-
backed, indication-specific and 
consistent products. 
 
Research and development must sit at 
the core of the industry to legitimise 
products, ensuring consistency and 
reputability for cannabis to be used as  
a medicine.
Chapter three discusses the UK’s 
CBD advantage. The UK has a unique 
headstart compared to the rest of 
Europe, bringing a period of regulatory 
uncertainty to an end. Clear regulation 
encourages investment and innovation 
as a serious and reputable industry.  
A clear path to compliance is a 
necessary step for moving the industry 
forward and ensuring consumer safety.
Chapter four highlights the next 
steps for the industry. There is rising 
competition in the European medical 
cannabis sector  in the form of pilot 
programmes and new emerging 
markets. As the continent prepares for 
a booming industry, it is essential to 
move quickly in order to capitalise on a 
valuable opportunity. More importantly, 
to continue growing the medical 
cannabis sector, patient access must  
be expanded as the industry cannot 
sustain itself without more patients.
Executive Summary
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Key Findings
1. The appointment of a ‘cannabis tsar’ or the 
creation of a governmental body in the UK to 
oversee the expansion of the UK medical cannabis 
industry. At the moment, regulatory matters 
must be processed through the Home Office. 
This is slowing down development due to a lack 
of a streamlined approach. A governmental body 
reserved for cannabinoid regulation, licensing and 
innovation funding is a necessary step towards 
further harmonising development in the sector.
2. The Food Standards Association should provide 
clarity around the amount of THC to be permitted 
in CBD products. Such regulatory clarity must 
be done in a way to ensure it encourages further 
investment and innovation.
3. The industry should engage with the British 
Chambers of Commerce in efforts to invest in 
innovation for the cannabis sector. This would 
further legitimise cannabis as a growth sector 
and contribute to research and development for 
expanding access to medicine. There should also 
be engagement with the National Farmers Union 
to represent producer interest as a means of 
diversifying crops.
4. As per the recommendation in the recent 
Volteface report Pleasant Lands, allowing hemp 
seed varieties with a THC percentage above 0.2% 
and up to 1% would improve the health of the plant 
and increase the yield of CBD per acre, and would 
not affect the end product, which could still have 
undetectable levels of THC present.  
This would allow the UK to compete with other 
non-EU countries, which are not bound by EU 
registered seed varieties, and would support the 
UK to become a hub of research and development. 
5. Simple amendments to legislation to facilitate 
the flow of products. Currently, customs and other 
legislative bodies are slowing down supplies and 
increasing costs. If these processes are simplified, 
costs will be reduced and patient access will be 
improved.
6. Amend the regulation requiring medical 
cannabis prescriptions to be made by doctors on 
the specialist register. This could be replaced by 
doctors undertaking a suitable CPD qualification. 
Ensuring that all doctors can prescribe medical 
cannabis is a huge and achievable win. The UK 
should follow in Germany’s footsteps in regards 
to how quickly the sector can grow if allowed. The 
UK should aim to help private patients achieve 
reimbursement on insurance.
7. Increase the evidence base for cannabis-based 
medicinal products in the UK in order to expand 
patient access on the NHS; this is essential to 
fully unlock the UK market. The only way of 
successfully achieving this would be through 
a government-funded national trial. Forming 
strategic partnerships with well-regarded UK 
medical establishments is essential in bringing 




of the UK medical 
cannabis market is 
£1.2 billion.
Number of jobs to 
be created in the UK 
medical cannabis 
sector is estimated 
at 41,437.
Number of 
ancillary jobs to be 
created in the UK 
medical cannabis 
sector is estimated 
at 17,000.
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Suppose someone told you that two innovative 
industries were poised to revolutionize 
healthcare and create tens of thousands of jobs 
in the process. They would contribute billions to 
our COVID-stricken economy whilst attracting 
global talent and investment to our shores. They 
would also showcase the benefits of divergence 
from the European Union. Anyone would take 
advantage of such an opportunity with open 
arms.
The industries in question are medical cannabis 
and CBD. The UK has already begun to 
embrace the potential of these nascent, fast-
growing markets: undoubtedly accelerated 
by the legalisation of medical cannabis in 
2018. Cannabis listings opened on the London 
Stock Exchange earlier this year, an advanced 
regulatory framework has created significant 
opportunities for future growth in domestic 
CBD businesses compared to their continental 
counterparts and the UK remains the largest 
exporter of medical cannabis in Europe.
The European market for medical cannabis is 
the fastest growing in the world and our unique 
position gives us the prospect of becoming a 
leading player in medical cannabis and CBD.  
This paper provides a fascinating overview of 
the state of play in these markets, opportunities 
for growth and the regulatory questions that 
face the sector. It shows how the UK is in a prime 
position to become the centre of the European 
medical cannabis and CBD industry, as well as 
the significant economic benefits that would 
result.  
It also examines the innovation opportunity 
inherent in these markets: embracing these 
sectors will help to attract the best and brightest 
scientists to the UK. We are internationally 
acclaimed for our leadership in research and 
development in countless sectors, and through 
two case studies this paper shows how medical 
cannabis and CBD are both fertile ground 
for driving innovation in medical and health 
products.
The UK has led the charge in ensuring our CBD 
industry is one of the first in Europe to be fully 
compliant with Novel Foods regulation while 
allowing the market to grow. The paper shows 
that companies involved in this space stand to 
benefit from the regulatory clarity this provides, 
as well as the associated boost to investment 
and consumer confidence through establishing 
high standards. The risks to competition from 
onerous regulatory burdens pushing out smaller 
businesses have also been mitigated through 
the European Industrial Hemp Association’s 
(EIHA) Novel Food Consortium, which has helped 
to reduce the cost of compliance by pooling 
applications for Novel Foods certification.
Despite our achievements to date in this area, 
we cannot rest on our laurels. There are still 
questions to be answered around appropriate 
legal limits on naturally occurring THC content 
in CBD products. If the limits are too harsh, we 
risk hamstringing the market just as it has the 
greatest opportunity to flourish and grow. 
For medical cannabis in the UK, the elephant in 
the room is the challenge of widening patient 
access. As the paper highlights, there are still 
substantial barriers facing those in need of 
prescriptions. Sensible regulation, encouraging 
investment into the sector and conducting 
further research on cannabis-based medicinal 
products are all vital components of ensuring the 
UK becomes a centre of excellence for medical 
cannabis in a way that benefits patients, not just 
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Medical cannabis and CBD are undoubtedly 
coming of age in the UK. Despite Brexit and 
Covid bringing a substantial amount of economic 
insecurity, 2021 is proving itself to be a year of 
promising opportunities.
As one of the few growth sectors, cannabis has 
demonstrated itself  to be a viable opportunity 
to combat economic uncertainty. Recently, 
cannabis has witnessed incredible global reform 
breakthroughs. Whether it is the UN’s historic 
vote, the EU court’s CBD ruling, more states 
legalising in the US or the introduction of medical 
cannabis programs across Europe - the world is 
warming to the idea of cannabis.
As the world’s fastest growing market, Europe 
is set to become a leader in cannabis. Looking 
closer to home, we witness the first cannabis 
company listings on the London Stock Exchange 
(LSE). By doing so, the UK has shown it is open 
for business.
Though many see cannabis as a niche industry, 
this is far from the truth. Cannabis is an 
interdisciplinary sector, requiring a wide-range 
of job roles for a variety of skill sets. Within a 
legal cannabis industry, everyone gets to profit 
with a massive ancillary revenue for all involved 
professional services. The opportunities for 
employment are vast and must be welcomed. 
Investment in the cannabis sector is also a vessel 
for innovation development through improving 
product quality, access and advancing our 
understanding of cannabis. Through this, the UK 
will be able to further its influence in research 
and development (R&D) in the sector.
The more the industry expands and diversifies, 
the more affordable products become for 
consumers. Greater product variety through 
innovation ensures consumers have a larger 
selection of products to choose from. This also 
prevents large players from monopolising the 
market, instead celebrating diversity. 
The UK has a booming CBD industry. It also 
stands in a unique and advantageous position for 
CBD regulation. The recent regulatory clarity 
and compliance with Novel Foods authorisation 
processes places the UK in an excellent place 
for innovation and investment. The clarification 
paves the way for normalising the industry, 
guaranteeing product quality and makes the UK 
an attractive jurisdiction to do business in.
The UK cannabis sector holds promise for 2021 
and beyond. Regulatory clarity and R&D are 
allowing for a vibrant and dynamic industry to 
develop. Industry growth with investment will 
continue to expand our knowledge of cannabis 
and greater knowledge will expand the industry. 
This two way process is poised for success.
Introduction: Turning Over A New Leaf
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There is no doubt that cannabis holds immense 
economic benefits. Recent developments are 
allowing the UK to become a hub for medical 
cannabis investment.
The UK is the largest exporter1 of medical 
cannabis in Europe. The first license to cultivate 
medical cannabis was issued in 1998 to GW 
Pharmaceuticals. Medical cannabis was legalised 
in 2018, though access still remains limited
On 18 September 2020, the Financial Conduct 
Authority (FCA) released an important statement2 
outlining a new approach for listing medical 
cannabis companies. This statement provided the 
necessary clarity for medical cannabis companies 
in the UK. This news was open and supportive 
of the market, allowing for investment and 
expansion of operations in the sector. 
In February 2021, the LSE opened its doors 
to medical cannabis companies. Listings have 
provided the necessary step for medical cannabis 
to become a legitimate and serious industry in 
the UK. Public investment is a huge step forward, 
opening up a new pool of capital. Successful listings 
have demonstrated the UK investor community is 
interested in cannabis, giving the green light to an 
immense opportunity. 
Over the last few years, North America has paved 
the way with medical cannabis with investment, 
vast job creation and taxable revenue. Although 
Europe is developing quickly, at present it has 
no obvious medical cannabis leader. The UK has 
the opportunity to take this position. As it works 
toward creating a new identity post-Brexit, the UK 
is no longer tied to EU decision making. This can be 
viewed positively for this space, allowing the UK 
to move faster and lead on a whole new level.
Recent news certainly positions the UK as an 
attractive jurisdiction to do business in for the 
medical cannabis sector. In due time we can expect 
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Table 1. Analysis of 10 Largest Cannabis Companies. Note: all values in GBP.
Chapter 1. The Economic Opportunity
In order to give a tangible estimate of what the UK’s 
cannabis industry could look like, an analysis of the 
largest global cannabis companies was conducted. 
The analysis highlights why the UK should be 
focused on becoming an investment hub given the 
profitability of the sector.
Major global players analysis




































58.8 million9 12.34 million 310
110.2 million11 24.14 million 112
26.7 million13 26.7 million 1714
450.9 million15 4 million 116
379.2 million17 94.69 million 4218
36.6 million19 72.04 million 120
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These figures demonstrate that the cannabis 
sector holds promise for the UK given the large 
sums of total and taxable revenue per company.
The number of employees simply acts as an 
indicator for the size of these companies. This is 
an indicator for the extensive size UK companies 
could grow to. The number of countries these 
global players are active in demonstrates the 
cannabis sector is a global opportunity for 
exporting and expanding internationally.
Market values and yearly revenue per company 
demonstrates the sector’s profitability. If the 
UK positions itself as  the  focal point of Europe, 
a significant pool of capital awaits for publicly 
listed companies. The more companies that 
list, the greater the pool of capital. This is also a 
compelling argument for a free market approach 
to the cannabis industry, which would further 
boost  the economic opportunity.
UK market size estimate
The following analysis of the major cannabis 
players gives an indication of the extent of the 
global opportunity. In order to calculate an 
accurate estimate for the UK market, a scale 
of the medical cannabis market was used for 
Germany, Italy, The Netherlands and several US 
states that only have a medical market. The UK 
population currently stands at 66.65 million. This 
existing market size was used and adjusted to the 








UK Market Size 
Equivalent (million)
Italy 15.7 60.36 17.34
Connecticut 42.9 3.565 802









Germany 105.79 83.02 84.93
Arizona 507 7.279 4,643.33
The Netherlands 9.36 17.28 36.10
Delaware 26.4 0.974 1,806.5
Table 2. UK Medical Cannabis Market Estimate. Note: All values in GBP







UK Market Size 
Equivalent (million)
Iowa 4.29 3.155 90.63
Ohio 157.3 11.69 896.84
Montana 65.8 1.069 4,102.5
New Mexico 92.9 2.097 2,952.69
Maryland 231.86 6.046 2,546.5
New Jersey 85.8 8.882 643.84
New York 89.39 19.45 306.32
Minnesota 27.9 5.64 329.7
Louisiana 3.57 4.649 51.18
Pennsylvania 290.3 12.8 1,511.6
New Hampshire 16.1 1.36 789
Average calculated UK medical cannabis market estimate: £1.265 billion
This analysis used 20 medical cannabis markets 
in the US and Europe to predict a UK medical 
cannabis market size. As this analysis uses inputs 
from a range of markets, the estimate has a 
certain amount of validity.
This UK market estimate demonstrates the 
immense economic opportunity the cannabis 
sector holds. By developing the UK into a 
European cannabis industry leader, this will hold 
a significant amount of capital, in the realms of 
£1.265 billion.
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The medical cannabis industry is clearly a 
profitable sector. The breadth of innovation is an 
attractive opportunity for businesses to flourish. 
Not only is it appealing for companies to make a 
large profit, it is an industry that employs a large 
number of people across all skill-sets. 
As various figures have been thrown around, it 
is worth investigating what a profitable industry 
in the UK could look like for widespread job 
creation.
This report has used existing, recently published 
data on the number of people employed in the 
US legal cannabis industry. In order for estimates 
to be as accurate as possible, US states that only 
have a medical cannabis market were included. 
Including states that also have a recreational 
market would not accurately represent the 
number of potential jobs in the UK.
The UK population currently stands at 66.65 
million25. The number of cannabis sector jobs 
and population for each state was included 
in the analysis. This was used to estimate an 
equivalent figure for the UK, proportionate to the 
population.
As is visible in the table below, the number of jobs 
in the medical cannabis sector varies massively 
across states. Though population plays a role, so 
does the number of patients and extent of the 
industry’s development.
In order to have the most reliable job estimate, 
an average for all 22 states that have only a 
medical cannabis market were included, to paint 
the most realistic estimate for the UK market. 
All job estimates have been multiplied by their 











































UK Market Size 
Equivalent (million)






















































Using estimates and averages from 22 US states 
with medical cannabis programs, the UK medical 
cannabis market could create over 41,000 jobs 
in the sector.
This is only an estimate based on data from the 
US. However, the larger the market and the more 
patients in the UK the greater the potential 
number of jobs in the industry.
This analysis is strengthened by using inputs from 
a range of US medical cannabis markets, giving 
this estimate a greater validity. 
It is evident that medical cannabis is a lucrative 
industry with the potential for immense job 
creation. The larger the UK industry becomes, the 
more job opportunities. Though the US industry 
is several years ahead of the UK, the cannabis 
industry already employs more people than 
computer programmers27 in the country.
However, job creation goes beyond direct 
employment in the cannabis sector. Ancillary 
revenue and job creation is another contributor 






UK Market Size 
Equivalent (million)
Average number of jobs potentially created in the UK: 41,437
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The development and growth of the cannabis 
sector has a direct beneficial impact to 
other industries. A thriving market benefits 
professional services involved in the industry.
Ancillary jobs include roles such as lawyers, 
accountants, consultants, media companies 
and marketing firms that service the industry. 
These jobs support the industry without direct 
involvement, demonstrating the widespread 
benefits of the sector stretching beyond the 
parameters of medical cannabis.
A report published by Leafly in 2019 estimated 
the number of indirect ancillary jobs created 
as a result of the legal cannabis industry to be 
85,000. This figure will have grown since 2019. 
Performing a rough estimate equivalent to the 
UK population, this would result in the creation 
of approximately 17,000 ancillary jobs for the 
medical cannabis industry.
With over a potential 41,000 direct and 17,000 
indirect jobs created by the medical cannabis 
industry, the UK stands in a strong economic place.
Estimates and predictions highlight the present 
economic opportunity for the UK is massive. 
However, for the time being the industry remains 
in a nascent stage. There is a clear appetite for 
investment in the UK but there is a paradox for 
patient access remaining difficult across the 
country.
As the UK emerges from Brexit and Covid, there is 
no better time to embrace cannabis and encourage 
investment.
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The cannabis industry undoubtedly holds 
immense opportunity for innovation. Currently, 
the UK is primed for innovation opportunities if it 
embraces the business case for cannabis. Coupling 
the evidence-base behind the efficacy of products 
and creative applications, innovation is a key 
driver for the expansion of the cannabis industry. 
This leaves the UK in a promising spot, especially 
as it has a global reputation for excellence in 
scientific research. However, remaining at the 
forefront involves furthering research and 
development (R&D) in the cannabis sector.
Cannabis brings unique opportunities for 
product development within a variety of existing 
innovations, which increase the effectiveness and 
appeal of medicines. Despite overlap, medical 
cannabis and CBD are each uniquely positioned 
with product development holding specific 
requirements to foster innovative thinking. As 
consumers within these markets have differing 
requirements,  it is most appropriate to discuss 
medical cannabis and CBD separately.
This chapter highlights the way forward for 
innovation and branding in the cannabis sector. 
This section of the report hones in on two case 
studies examining medical and wellness products. 
Case Study 1 examines Kanabo and their 
groundbreaking medical cannabis ‘VapePod’. The 
focus on Kanabo  originates from the success of 
their recent listing and their proven investment 
clamour.
Case Study 2 examines leading company 
CiiTECH, exploring why R&D must sit at the 
core of brand development to legitimise CBD 
as a health product. CiiTECH is a relevant case 
study with their approach to innovation through 
research in the sector.
The Israeli R&D company, Kanabo28 was founded 
in 2016. Kanabo’s commitment to research has 
led to the development of high-quality cannabis 
extract formulas, innovative medical grade 
vaporisers and various non-smoking consumption 
solutions. They have recently become the 
centrepiece for medical cannabis innovation as 
the first company to be approved to list on the 
LSE, making their market debut on February 16 
2021. 
The present case study is based on insights from 
Michelle Tamir, Marketing and Sales Manager at 
Kanabo.
“The importance of innovation in the cannabis sector 
comes down to taking something that has been 
an illicit, agricultural product used throughout the 
millennia and consumed through rudimentary ways. 
These are Tier 1 Products and have been around for a 
long time. 80 years of cannabis prohibition has not let 
this process evolve at all. Whereas, regulation allows 
us to apply a framework to the market with supply 
chains and a scientific method. This allows for the 
development of products that are medical, placing 
us in the same territory as doctors. This permits us to 
go down to the molecular level, understand how the 
cannabis plant works and how it can be applied in 
different ways to create new products.”
Innovation is a means of advancing medicine. 
Known for their development of the VapePod, 
the history behind Kanabo’s product comes from 
Avihu Tamir, Kanabo CEO Founder’s personal 
story. After being prescribed medical cannabis, 
Avihu was sent to a nurse to learn how to roll 
cannabis cigarettes. Finding this medically 
unacceptable, it sparked a Eureka moment, with 
Tamir realising that there must be a better way 
of consuming the plant. This led to the founding 
of Kanabo and the journey to develop proper 
formulated medicine.
What makes cannabis unique as a medicine is the 
way in which it is most effectively consumed.  
 
This is reflected in the consumer choice to smoke 
cannabis, due to the fast onset of effects.  
Chapter 2. The Innovation Opportunity
Case Study 1: Kanabo
The New Leaf: Beyond Brexit, Countering Covid 15
However, this unhealthy method of consumption 
is one of the key reasons why doctors fail to see 
cannabis as a medicine.
Bioavailability is one of the most important 
aspects to cannabis innovation. Bioavailability is 
determined by the properties of the drug dose, 
referring to the extent and rate at which a drug 
enters the circulation when it is introduced in the 
body and thus is able to have an active effect. 
Smoking cannabis gives high bioavailability, 
absorbing a high amount of the product with 
a rapid onset of effects; hence reflecting the 
consumer choice to smoke. Whereas edibles only 
absorb approximately 5-10% of the product. The 
effects of edibles are also experienced differently 
by individuals, meaning there are a range of 
different effects, which for a medicinal product can 
be problematic to administer.
Innovation for medical cannabis  derives from 
developing “Tier 2” products that offer high 
bioavailability and a fast onset without necessarily 
being inhalation and edible products. Kanabo 
has taken this effective consumption method 
and applied it to the “VapePod”, to medicalise 
smoking. This gives not only a healthy alternative 
but also a more accurate dose.
“Once we advance the bioavailability, cannabis 
medicine moves into the language that doctors speak. 
If these products can offer a consistent measure, much 
like taking an aspirin pill with the same effect every 
single time, the product has succeeded as a medicine. 
Medicines require consistent packaging and consistently 
the same effects for each person that consumes it. 
When that has been achieved, physicians can prescribe 
cannabis. Consistency is what allows it to become 
mainstream, breaking down the barriers to prohibition 
and unlocking the therapeutic benefits of the plant.”
Ensuring product consistency and reputability 
is essential for any medicine. There are plenty of 
cannabis vaporizers on the US market. Although 
these are increasing in popularity, regulation has 
yet to catch up. Companies want a quick product, 
without necessarily considering the consumer,  
 
which leads to the creation of under-researched 
products with sub-par materials.
For these exact reasons, Kanabo’s VapePod is 
an exciting and relevant cannabis innovation. 
Though it may look similar to standard products 
on the market, the VapePod sets itself apart as a 
vaporizer that ensures patients receive a metered 
dose, providing exactly 1mg of cannabinoid 
extract. This is more precise than smoking 
cannabis flower where it is impossible to ensure 
consistency.
The mechanism is essentially the same as 
an e-cigarette. However, the VapePod uses 
sealed tamper-proof cartridges that cannot be 
manipulated, ensuring consistency and safety 
from additives. The device also has an automatic 
stop function. When the consumer inhales 
there is haptic feedback indicating the dose 
has been administered; the device then shuts 
off automatically. No matter how hard or soft 
the consumer drags, the VapePod delivers the 
exact same amount of product each time. This 
ensures a specific amount can be prescribed, 
whilst remaining easy to administer. The VapePod 
is a necessary innovation, which effectively 
medicalises vaping.
“What is also unique is that the VapePod was 
developed with the consumer in mind. It is very 
easy to use with no buttons and minimal cleaning 
required. To clean the VapePod, one simply needs 
to take a cotton swab with a drop or two of rubbing 
alcohol and wipe away dust particles from the 
connection components every once in a while. 
Whereas other devices, especially those meant for 
dry flowers, require a deep cleaning that can be 
rather time consuming and would require a set of 
tools to do so. It uses a simple design with a place to 
insert the cartridge and is light to hold in your hand. 
This user friendly design is essential, particularly for 
patients that have dexterity or mobility issues.”
Developing the VapePod resulted in several 
years of getting the product to a level where it 
would be accepted by the medical establishment 
with a process of approvals. Materials and 
manufacturing processes had to be GMP 
production approved. The device also had to be 
tested by a third party, setting itself apart from 
other products on the market.
The VapePod can be used to treat a range of 
conditions. As an R&D company, Kanabo plans to 
perfect formulas to cater to specific conditions. 
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Cannabis medicines are not a “one size fits all” 
paradigm. Thus, developing specific formulations 
for conditions will be the next step for product 
innovation.
With a lot of conservatism still surrounding the 
cannabis industry, there are certainly challenges 
ahead. However, innovations like the VapePod 
will be the gateway for demonstrating the 
worthiness of conducting research to medicalise 
current methods of consumption and making 
physicians more comfortable prescribing cannabis. 
Ultimately, this leads to more prescriptions being 
offered to patients, broadening the access to and 
acceptance of cannabis medicines.
Kanabo continues to think of ways of developing 
user-friendly, medical-grade products. Moving 
forward, we can expect to see a wider spectrum 
of products that further accommodate 
for mobility issues. Kanabo is successfully 
spearheading innovation frontiers for medical 
cannabis. 
As we slowly break down the global barrier of 
cannabis prohibition, incredible innovations will 
continue to emerge. The renaissance currently 
being experienced will allow the cannabis sector 
to flourish.
CiiTECH29 is a leading consumer-focused CBD 
company engaged in ongoing cannabinoid 
research, focused on discovering and 
commercialising cannabis products. Founded in 
2017, in the midst of a growing yet unregulated 
CBD industry, CiiTECH aims to create strong 
consumer connections by bringing research-
led formulations and innovations directly to  
consumers. They created Provacan30, a leading 
CBD brand both in the UK and across the globe. 
Through this, CiiTECH aims for regulation and 
standardisation within the industry, recognising 
the differing regulatory frameworks in each 
territory.
CiiTECH has remained at the forefront of the 
CBD industry through cannabinoid research 
conducted in collaboration with The Hebrew 
University. This investment in clinical research 
has helped generate a body of knowledge on 
cannabis health by partnering with scientific 
and medical communities. All of CiiTECH’s 
endeavours are inspired by science and driven by 
data insight. 
This case study is based on insights from Clifton 
Flack, Founder and CEO of CiiTECH. 
“The most innovative aspect to this industry has 
been transforming cannabis into a health product by 
approaching it through a new lens. This means, taking 
something that has been around for centuries and 
transforming it into something new and regulated 
that holds multiple uses. Innovative thinking gives 
cannabis incredible potential by allowing the industry 
to continue developing new and more effective 
cannabis healthcare products.”
CiiTECH is focused on addressing the problem 
cannabis currently faces as medicine, which is 
a lack of clinical research and evidence. This 
makes it important to change how the problem 
is approached to see results - innovation is this 
realisation. CiiTECH has done an incredible job at 
recognising where cannabis sits and how it should 
be regulated - from this, products that fit this 
criteria can be developed.
CiiTECH’s philosophy stresses innovative 
thinking for the cannabis sector, particularly 
honing in on brand development. This is a 
particularly important aspect for CBD as it 
remains a consumer choice. This highlights 
the different considerations required for CBD, 
compared to medical products.
Building a trustworthy brand is  essential for 
innovation. To build interest in CBD, brands must 
be founded on  trust and support. This can be 
accomplished through the industry engaging in 
innovative thinking to develop CBD’s reputation 
as a health product based on evidence, science 
and medicine.
Case Study 2: CiiTECH
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“The CBD space needs regulation but not necessarily 
anything new or innovative. Instead, the industry 
requires transparency and standardisation. This 
is exactly what novel food certifications are for, 
formalising the process for CBD to be regulated  
as a food supplement.”
If CBD is to be as large as it is forecasted to be, 
synthetic lab-based products will be the most 
appropriate means for approaching the market as 
a large company. This will not only allow products 
to be safely regulated but further expedite the 
process at which they are produced.
“Full spectrum products certainly have a place in  
the industry. However, among large industry players 
it is difficult to ensure a safe and secure format. The 
industry is currently under a significant amount 
of pressure around regulation, making synthetic 
lab-based products a viable alternative to continue 
formalising the sector to allow the industry to scale 
up and wide. The cosmetics industry will certainly  
be the heaviest users of synthetic cannabinoids.”
This highlights the broader issue of control 
and regulation for CBD products. CBD is one 
compound of many and the only way to effectively 
isolate it is synthetically. This means we can expect 
to see more isolated products on the market. This 
will allow CBD to begin fusing with the medical 
world as individual compounds are regulated.  
CiiTECH sees the innovative mechanism behind 
CBD as encompassing brand development. 
The scalable nature of this industry is down 
to building trustworthy brands; ones that are 
dynamic and flexible to meet consumer needs  
and ensuring strong product market fit in each 
local territory or target market.
CBD is an interesting product as it sits right 
in the middle of ‘recreational’ and ‘medical’, as 
a therapeutic product. Research has shown 
CBD’s efficacy, most commonly to treat anxiety, 
insomnia, pain and depression. 
A key way to remain at the forefront of the CBD 
industry through the incorporation of  scientific 
research into products. Investment and revenue 
can then go directly into funding more research.  
As already highlighted, this is what makes 
CiiTECH a unique and reputable company.  
 
Revenue is directly invested back into ongoing 
research projects and partnerships, that then 
spearhead new product development.
Two exciting products that are due for market 
release in the US have been created with patent 
pending formulations developed with the Hebrew 
University. These are CBD products in pill form 
to treat a) fatty liver disease and b) symptoms 
of the alcohol hangover. They are unique in 
their scientific backing and their use of existing 
remedies coupled with CBD. Both products are  
in high demand for consumers.
CiiTECH invested in a clinical trial examining the 
effects of CBD and CBG for fatty liver disease.  
Studies investigated how these compounds would 
improve obesity invitro and in mice and  found 
that obese mice lost weight.
These findings are not necessarily new, as 
cannabis formulas are already being used for 
weight loss. However, CiiTECH’s research 
discovered which cells absorb and store fat 
and which  genes in the cell influence this. The 
formula CiiTECH have developed mirrors this, 
not absorbing or storing fat as energy. What 
this means for CiiTECH is a product that is a 
non-psychoactive and not controlled patented 
formula with CBD/CBG. 
The food supplement formula will be marketed 
as a unified weight management product. What 
makes the product unique is that it contains 
CBD/CBG but with added compounds that are 
already being used for weight management, such 
as apple cider vinegar. Essentially, what CiiTECH 
has done is create a weight management pill using 
zcompounds that are known to benefit weight 
loss.
CiiTECH’s hangover product follows the same 
concept as the weight-loss formula. A scientific 
method was used at the Hebrew University utilising 
the benefits of CBD along with other compounds 
known to alleviate hangover symptoms.
These products highlight CiiTECH’s philosophy 
of using innovative thinking which encompases 
already commonly utilised scientific methods, rather 
than something entirely new. These products are 
reinventing and rebranding solutions that already 
exist on the market, adding a patented CBD formula.
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Products such as these are indication specific 
and are not medical. There is no expectation 
for doctors to prescribe remedies, but what 
makes them unique and appealing is that they 
are backed up by well-researched evidence, 
combined with existing compounds that are 
known to work. 
“This is generally where we will see the CBD industry 
move toward, using CBD and other compounds to 
harvest a further effect. This will further distinguish 
between what products are aiming to achieve. The 
potential effects CBD can have are vast. By having an 
indication specific purpose, this allows products to be 
branded easier if they have a targeted function.”
In summary, CiiTECH’s science-led approach 
to building brands, product development and 
consumer connections is innovative, as it is both 
underpinned by existing scientific and medical 
approaches whilst utilising CBD.  
Taking existing ingredients already known to 
consumers and combining them with CBD means 
that consumers already associate the formulations 
with certain indications, pump revenue into funds 
for further research and view it to be a reputable 
company with trustworthy products.
CiiTECH is a unique CBD company with its 
dedication to an evidence-driven approach for 
CBD innovation. This is a sustainable model which 
uses data-driven insights to fuel brand value. For 
a CBD company to successfully immerse itself in 
the health industry they must establish credibility 
and display similarities with a healthcare company. 
This means looking further than simply sticking 
products on shelves. Involvement in research and 
grassroot education is imperative.
Innovation is a crucial element in developing 
the cannabis industry and unlocking further 
opportunities. Innovation is the only way to 
recover from decades of cannabis prohibition, 
fostering new growth.
As a highly interdisciplinary field, development 
must occur within the appropriate parameters. 
The First Wednesday’s European Medical 
Cannabis Ecosystem31 has done an excellent job 
highlighting how the industry can effectively 
operate within interdisciplinary parameters; 
innovation within each section of the ecosystem 
leads to a flourishing industry.
There is certainly a continued focus on innovation 
in the UK. A recent policy paper32 published by 
the UK government has formed a new Task Force 
on Innovation, Growth and Regulatory Reform. 
This will identify and develop proposals in a range 
of areas to drive innovation for the UK economy. 
This demonstrates that  innovation opportunities 
and areas for growth are being taken seriously by 
the UK government.
As an emerging market, R&D has the real potential  
to flourish. The renaissance and recognition of 
the potential cannabis has, demonstrates how 
investment and fresh thinking will continue to 
benefit the sector. We can expect to see further 
innovation in the sector, bringing new products 
to the market. This is a necessary advancement, 
particularly alongside much needed regulatory 
clarity in the sector to legitimise the industry.
The way forward
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The UK has a booming CBD industry. As it is 
currently worth £300 million33 and estimated 
to grow to £1 billion in the next five years, the 
sector is poised for positive development. The 
cannabis sector has witnessed the transformation 
of CBD into a  mainstream industry with products 
available on every high street corner in the UK, 
including  in well-known chains such as Holland 
& Barrett and Boots over the last few years. The 
implementation of novel foods will likely see a 
number of major high-street players enter the 
space. 
Compared to the rest of Europe, the UK has 
an advanced and lucrative CBD market. More 
importantly, the regulatory clarity provided by 
the Food Standards Association34 (FSA) on novel 
food authorisation guidance for CBD, places the 
UK in a unique position and ahead of Europe.
The following chapter was constructed and guided 
by insights from Robert Jappie. Robert is a Partner 
at Ince Gordon Dadds LLP, specialising in life science 
and cannabinoid regulation for the UK and Europe.
Before this report delves into the practicalities 
around why the UK is at an advantage for CBD 
regulation, it is important to unpick what the 
novel foods process means.
A novel food under European Law35 is a 
product that does not have a history of human 
consumption prior to May 1997. The regulation36 
was introduced to establish safety mechanisms to 
control newly developed foods.
In January 2019, the European Commission37 
reaffirmed that CBD extracts and isolates were 
to be listed in the novel food catalogue. The hemp 
plant itself and related products (i.e. seeds and 
cold-pressed oils) were not included in this ruling, 
as they have a history of human consumption 
prior to 1997 in European markets. However, 
once those raw extracts are placed through 
additional refinement processes, then a novel 
product is created, and novel food approval is 
required to prove product safety. Though the UK 
has left the EU, the UK government continues to 
implement the novel food regime and therefore 
the ruling on the novel food status of CBD stands. 
Novel food regulations are ultimately about 
consumer safety. A common misconception 
around the novel food process is that it is a legal 
submission, when in fact a novel food dossier 
application is entirely a technical, scientific 
submission. As CBD products are marketed to be 
consumed every day as a food supplement, then 
consumers need to be confident that it is safe to 
consume  such a product daily. This is the purpose 
of the novel food regulations.  The central part of 
a novel food submission is a detailed toxicology 
study, which provides a clear route to establishing 
safety data, enabling laboratories to establish 
the long-term impacts of CBD consumption by 
extrapolating data from studies lasting a matter 
of months.
Chapter 3. The UK CBD Advantage
Novel Foods explained
The New Leaf: Beyond Brexit, Countering Covid 20
In normal circumstances, full marketing 
authorisation is required before a novel food 
can be lawfully sold. The UK has set out a 
unique position for CBD novel food compliance. 
The FSA has granted an exemption for CBD 
products, which requires CBD companies to 
achieve compliance via a validated novel food 
submission. A deadline for submission of the 
novel food dossier was set for March 31 2021. 
This pragmatic approach allows existing products 
to continue being sold, with the expectation of 
achieving novel food compliance by the deadline.
“Novel food compliance should be viewed positively 
as it has imposed regulation via a phased approach 
which allows  the industry to continue developing. 
This regulatory clarity has given the UK a route to 
compliance for CBD products. Though it has been 
extremely difficult, costly and a time consuming 
process, it is undoubtedly a necessary step in moving 
the industry forward”
It is important to highlight the advantage novel 
food regulations provide for the industry. There 
is no higher standard in the world for food 
quality and safety than novel food certification. 
By requiring CBD companies to engage in this 
process, it ensures consumer confidence and 
market stability; both of which are a necessary 
step for legitimising the industry, attracting both 
further investment and mainstream interest.
The advantage of novel food regulations has 
been a neglected aspect to the debate. Whilst 
the drawbacks of regulatory hurdles have been 
stressed, the long-term implications these 
regulations have for the CBD sector have not 
been considered in detail. Achieving novel food 
compliance will allow CBD companies to set the 
highest standards in the global industry.
The UK’s novel food regime has diverted away 
from European procedures. This has had a 
positive impact on the UK industry, whilst 
creating obstacles for the rest of Europe.
Regulatory compliance is a complex space 
to navigate. This makes clarity all the more 
important and is what currently sets the UK 
apart from the rest of Europe.  This lack of clarity 
across Europe creates problems for regulation in 
individual countries. There are two recent cases 
that highlight this.
The landmark KanaVape case is an example of why 
clear regulation is essential for the CBD industry, 
which would act  as a catalyst for sector growth.
The Kanavape ruling
In November 2020, the European Court of 
Justice ruled that CBD should not be classified 
as a narcotic. This ruling was in relation to the 
prosecution in France38 for KanaVape, a company 
selling CBD products containing oil extracted 
from the whole hemp plant. Under French law, 
only the fibre and seeds of hemp can be used for 
commercial use, not the flower. The ECJ ruled 
that the French ban on CBD extracted from the 
whole plant contradicted EU law on the free 
movement of goods.
“The KanaVape case is an excellent example of how a 
seemingly small and insignificant case can have huge 
ramifications on the industry. Although very positive, 
and a relief to the industry, every member state is still 
responsible for its own legislation meaning the case 
was not a direct game changer for CBD. It further 
highlights that need for a clear route of compliance 
for CBD companies across Europe”
This case is already having an impact, forcing 
the European Commission to recommence 
consideration of Novel Food applications. We 
can expect to see more decisions like this, as 
the ruling highlights the need to establish a 
streamlined European market for CBD products 
as many products are still being sold in a 
regulatory grey area in the EU.
The UK’s Head Start
The European Dilemma
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The Little Collins case
The ongoing case of Little Collins CBD 
Dispensary in Ireland perfectly highlights the 
problem a lack of regulatory clarity creates. Little 
Collins is an independent business selling CBD 
oil and hemp flower products, including herbal 
remedies, teas and oils. The shop has been raided 
several times by the police. The case has been 
taken to the Irish Higher Court, challenging the 
prosecution that selling certain hemp products is 
invalid under EU Law.
Due to such regulatory grey areas, the situation 
in Ireland is profoundly incoherent and difficult 
to navigate. This has meant that  small and 
independent businesses are unfairly targeted in 
these raids. Unfortunately, these businesses have 
little protection from such raids. 
What’s happening in Ireland is indicative of the 
risk for all European countries, as authorities 
have a wide discretion on whether to crack 
down on novel food regulations. Cases like this 
could have posed a risk for the UK without the 
FSA exemption. As a result of this, raids like this 
should not occur in the UK. However, so far no 
other European countries have followed the UK’s 
example.
Although there is a growing CBD market in the 
EU, due to a lack of regulatory clarity, there is still 
a great deal of risk associated with this  sector. If 
the CBD industry is to be sustainable, regulation 
must be addressed. The clarity provided by novel 
food regulations in the UK is the first step in 
removing risk from the sector.
Though Europe faces challenges in terms 
of  CBD regulation, there have been positive 
developments in the sector.
Whole plant-derived CBD has been added as a 
legal ingredient in cosmetics in the EU. Although 
some forms of CBD were previously allowed, only 
CBD extracted  from the seeds and stems were 
permitted. This was unnecessarily restrictive. 
With whole plant extracts now allowed in 
cosmetics, this is a positive for the European 
cosmetics industry. 
Strict regulations can, of course, be accompanied 
by the sad reality that smaller companies 
are pushed out of the market. However, the 
European Industrial Hemp Association39 (EIHA) 
has encouraged smaller companies to join 
their membership. As this is a legally complex 
area, the EIHA plans to achieve security for the 
industry by leveling the playing field for SMEs. 
This has been achieved by creating a novel food 
consortium, which allows companies to submit 
a joint application and share the costs burden. 
For an individual company to prepare a dossier 
submission, the costs can be as high as €300,000, 
thus  this consortium offers SMEs a helping hand 
in achieving novel food compliance.
Although the enforcement of the novel food 
regime will undoubtedly reduce the number 
of companies in the market, we don’t want this 
industry to be the preserve of only big companies. 
The EIHA initiative is an example of how an 
inclusive, supportive and reasonable approach to 
keep the market open can be achieved.
Positive developments
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Although the pathway to regulatory compliance 
is now known in the UK, the level of enforcement 
that will take place is still to be determined.
“Post-deadline, products not covered by a validated 
novel foods application face the risk of being removed 
from sale. Companies that have spent significant 
amounts of money for novel food applications, will 
be expecting enforcement to take place. Enforcement 
will fall to Trading Standards, who will have been 
briefed by the FSA to intervene in relation to non-
compliant CBD companies. It remains to be seen 
what resources will be made available to local 
authority trading standards to carry out enforcement 
actions”
From April 1 2021, we may start to see some 
self-regulation within the industry taking place, 
with compliant companies on the lookout for non-
compliant competitors. Of course, there has to 
be a balance between regulatory compliance and 
free market flexibility. We don’t want compliance 
obligations to be so onerous and expensive that 
only the biggest companies can survive.
As the CBD industry now employs a lot of 
people, the government should be encouraging 
businesses to grow whilst operating in a 
compliant fashion. Regulation of the CBD 
industry will feed into the broader topic of market 
consolidation that is taking place across the 
cannabis sector. Thus, the UK CBD industry must 
look for steady and sustainable growth, which  
may mean looking for synergies with like-minded 
companies.
How will compliance be enforced?
Post-novel foods, the next issue for the UK CBD 
market is THC content. The question around the 
amount of THC, which should be permitted in 
CBD products is certainly a discussion occurring 
in government. However, it needs to be addressed 
in a way that supports businesses rather than 
hinders them. If harsh restrictions are put in place 
for THC content, then the expense and effort 
used up in achieving novel food compliance will 
be for nothing.
We are already seeing the industry prepare for 
this, with the EIHA launching a clinical trial to 
establish safe THC levels40 in CBD products. 
This will be the largest study of the toxicological 
impacts of human ingestion of trace levels of THC 
in foods. This evidence will help establish a base 
for regulators of permitted levels of THC.
THC content is an area that requires clarity, 
but must be conducted in an open and positive 
manner. The Home Office has been looking into 
what is an acceptable amount of THC to have in 
products; this is evidenced by the recent letter to 
the ACMD on THC content from Kit Malthouse41, 
who is the relevant under secretary as Minister 
for Crime and Policing. In the letter, he highlights 
why this is an issue that needs to be taken 
seriously and needs addressing. 
Though there have been many arguments for 
and against novel food compliance, the UK’s CBD 
advantage hopefully brings a period of regulatory 
uncertainty to an end. A clear path to compliance 
is undoubtedly necessary for consumer safety 
and moving the industry forward.
We hope that regulatory certainty will encourage 
further investment and innovation in the cannabis 
space. Mainstream companies will be increasingly 
likely to enter the sector, creating new jobs and 
revenue, ultimately boosting the UK cannabis 
industry.
Where do we go from here?
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Europe is rapidly becoming a central hub for 
medical cannabis as the fastest growing42 market 
globally. This is driven by the opening of new 
markets  and an increased demand for medical 
cannabis reform. 
Recently, the industry has witnessed fast 
developments which have capitalised  on 
cannabis across Europe. It is clear the continent is 
preparing for a booming industry.
Given the advantages highlighted in this report, 
the UK has the opportunity to become a medical 
cannabis leader in Europe. Though in a strong 
position, there is work to be done.
Work must be centred around increasing the 
number of medical cannabis prescriptions and 
expanding access. The UK must move quickly to 
ensure a valuable opportunity is not missed as 
European competition continues to increase.
This chapter sheds light on Denmark and France. 
Both have been chosen as examples for how 
medical cannabis pilot programmes are being 
implemented. This will be used to highlight what 
this means for the European market and for UK 
expansion.
Denmark launched their four-year medical 
cannabis pilot programme in 201843. The 
programme permits doctors to prescribe 
cannabis products that were previously illegal in 
Denmark. The purpose was to offer a legal way 
to test medical cannabis treatment and expand 
access, to provide a better basis for assessing its 
use and efficacy. This established a controlled 
framework by which medical cannabis could be 
prescribed.
Following this, in November 2018 the 
government allowed bulk exports of medical 
cannabis. This makes the Danish model unique 
as it has  a trial for medical use and cultivation 
in progress. Patients have been prioritised for 
the trial, but emphasis has also been placed on 
exporting cannabis for economic benefits. This 
has allowed Denmark to make a big name in the 
space once the programme is over.
The Danish medical cannabis industry continues 
to thrive as a safe entry-point for companies 
wishing to enter the European market. Denmark’s 
high but transparent regulations have been an 
excellent means for establishing themselves, 
further highlighting the benefits of a regulated 
market. The programme has established expertise 
in pharma and horticulture, whilst maintaining 
commitment to innovation and sustainability.
Under the programme, companies can obtain a 
license to cultivate, manufacture, import and sell 
cannabis medicine. So far, the pilot has been a 
resounding success44 with an increase in doctors 
prescribing and patients receiving medicine.
Through their pilot programme, Denmark has 
been established as a key, leading player in the 
European medical cannabis industry. This has 
been an excellent ‘foot in the door’ for a thriving 
medical cannabis market through attracting 
leading industry players. The programme has 
had a domino effect on the rest of Europe with 
other countries adopting medical cannabis 
programmes.
Chapter 4. Increasing European Competition
Denmark
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France is due to commence their two year 
national medical trial targeting 3,000 patients 
suffering from a range of conditions including 
cancer, epilepsy, multiple sclerosis, palliative care 
and pain.
As the first nationally authorised non-commercial 
patient trial in Europe, this is bound to advance 
the medical market. If successful, the trial could 
be a big step for developing the French sector.
As one of the centrepieces for European cannabis 
discussions in 2021, France could become a 
significant player in expanding patient access. 
This could lead to expanding operations in Europe 
as the result of meaningful data gathered from 
the trial. 
 
With the trial only just starting, there is no 
guarantee that the programme will be a success, 
but this is certainly a step forward for  market 
development and increased access.
Investment in the nascent UK cannabis sector is 
undoubtedly booming. More listings are making 
a positive splash for the industry. The case has 
been made for the UK opportunity through 
an economic, innovation and regulatory lens. 
With growing interest in the European medical 
cannabis sector, the UK must move fast to ensure 
they don’t miss out.
However, if the medical cannabis industry 
really wants to make a difference and witness 
widespread reform, access for patients must be 
expanded. The industry cannot sustain itself if 
patient numbers do not increase.
The UK medical cannabis landscape is still filled 
with barriers. There is a reluctance to prescribe 
cannabis, with only a handful of prescriptions 
issued by the NHS since the law changed in 2018. 
Approximately 2,500 patients access cannabis 
through a private prescription. However, this is 
financially inaccessible to most, reflected in the 
1.4 million45 ill people who have illicitly accessed 
cannabis to self-medicate. 
The medical cannabis industry cannot and will not 
continue expanding without more patients. Thus, 
expanding access for patients must be a priority 
and investment can help make this happen. 
Pouring money into the industry can broaden 
access and drive down the price for patients.
Another barrier for the sector is that cannabis 
does not look or feel like a medicine to doctors. 
The variety and lack of control when prescribing 
flower-based products means cannabis is not 
viewed as a medicine. The incredible innovations 
emerging are a key way for improving the efficacy, 
regulation and control over cannabis medicines.
The UK industry is taking off with a quickly 
changing landscape. Though things are looking 
good, there is more work to be done. If the UK 
wants to continue developing into a key industry 
leader, it must look into a controlled framework 
for medical cannabis access. Access must be 
expanded to get medical cannabis properly off its 
feet and see long term development.
France
Call to action



























































































The New Leaf: Beyond Brexit, Countering Covid 26
36. https://eur-lex.europa.eu/legal-content/EN/TXT/
PDF/?uri=CELEX:31997R0258&from=DE 
37. https://canex.co.uk/cbd-products-novel-foods-deadline-
looms/
38. https://www.theguardian.com/society/2020/nov/19/cbd-is-
not-a-narcotic-says-eu-court-french-ban
39. https://eiha.org/eiha-novel-food-consortium/
40. https://businesscann.com/clinical-study-on-200-people-aims-
to-establish-safe-thc-level-in-full-spectrum-hemp-extracts/
41. https://www.gov.uk/government/publications/advice-on-
consumer-cbd-cannabidiol-products/letter-from-kit-malthouse-
to-acmd-chair-accessible-version 
 42. https://www.prnewswire.co.uk/news-releases/cannabis-
market-worth-90-4-billion-by-2026-exclusive-report-by-
marketsandmarkets-tm--870104395.html 
43. https://investindk.com/insights/a-new-2020-feature-on-the-
medical-cannabis-marketing-in-denmark 
44. https://www.njordlaw.com/what-is-the-status-on-medical-
cannabis-industry-in-denmark-2020
45. https://canex.co.uk/more-than-one-million-uk-adults-
eligible-for-new-medical-cannabis-card/#:~:text=In%20
the%20UK%2C%20there%20are,on%20cannabis%20from%20
illicit%20sources
References
/voltefacehub
www.volteface.me
